Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...